Bubendorf, Switzerland, Saturday, June 5, 2021 – CIS Pharma’s new lens care patent application was published. The patent covers the latest developments in the field of contact lens care creating multi-purpose disinfecting solutions, MPDS, with an improved efficacy/safety profile. CIS Pharma’s innovation reduces the trade-off between efficacy and safety, inherent to MPDS that cover the complete contact lens care regimen with just one product.
CIS Pharma technology combines the use of three disinfectants that synergistically offer a high disinfection power. The chosen disinfectants result in shorter disinfection times and offer efficacy even if the lens wearer does not comply with the instructions for use, e.g. re-uses the same solution over time. In addition to the higher disinfection power, the technology allows for higher concentrations of comforting agents, such as hyaluronic acid, HA, in comparison to state-of-the-art products. Higher concentrations of HA have a positive effect on corneal health and comfort when inserting and wearing contact lenses. Corneal epithelial cells show higher migration and proliferation. Also HA is released from the contact lens over a longer period of time. CIS Pharma has an expertise of over 30 years in the contact lens care market, licensing and manufacturing products to market leaders in eye care.